Peptides9 min read
What the 2025 amycretin trial actually adds
The injected amycretin study produced a striking early weight signal. Its five-part design, intensive monitoring and withdrawals determine what that signal can mean.
Read articleBlog
Research, explained. Explore peptides, supplements, hormone health, longevity and red light therapy with clear, practical breakdowns of what the studies actually tell us.
Peptides articles
All articlesMetabolism, recovery and emerging research
Peptides9 min read
Thymosin beta-4: why eye drops, wound gels and injections differ
Eye drops, gels and intravenous thymosin beta-4 reach different tissues and answer different treatment questions. Here is what the human studies establish.
Read article
Peptides8 min read
Thymosin beta-4 and corneal repair: closure, comfort and vision
Corneal wound closure, comfort, sensation and vision are different outcomes. The SEER-1 eye-drop trial helps explain what thymosin beta-4 has and has not shown.
Read article
Peptides7 min read
GHRP-6 versus GHRP-2: appetite, hormones and clinical evidence
Compare GHRP-6 and GHRP-2 by the outcomes actually studied: hormone responses, appetite, repeated exposure and Japan's pralmorelin diagnostic indication.
Read article
Peptides9 min read
Semax and long-term cognitive safety: what short studies leave unanswered
Short imaging and neurological studies cannot establish the safety of years of cognitive-enhancement use. Here is what they observed and what remains unknown.
Read article
Peptides9 min read
GHK-Cu and the 4,000-genes claim: what gene expression can tell us
Trace GHK’s 4,000-genes claim to its cell-line data and learn why RNA changes, functional cell tests, and human treatment benefits are different evidence.
Read article
Peptides9 min read
CJC-1295 studies were short: what remains unknown about longer use?
Early human studies, overlapping cohorts and mouse pituitary findings leave important questions about prolonged CJC-1295 exposure.
Read article
Peptides8 min read
Survodutide in type 2 diabetes: what a 16-week trial can tell us
The early diabetes trial lowered HbA1c and weight, but its experimental schedules and short follow-up matter when interpreting the results.
Read article
Peptides9 min read
Why phase 2 and phase 3 survodutide percentages need context
Why survodutide's 46-week and 76-week results differ, including actual versus assigned dose, placebo response and analysis methods.
Read article
Peptides9 min read
How to read a pemvidutide announcement without losing the clinical meaning
Follow the IMPACT announcements from topline results to the full paper, while keeping biopsy endpoints, digital analyses and later follow-up distinct.
Read article
Peptides9 min read
What eloralintide needs to demonstrate beyond early weight loss
The next eloralintide questions concern durability, diabetes, physical function and safety—not simply a larger weight-loss percentage.
Read article
Peptides9 min read
Petrelintide's early weight result: what 8.6% means
The early 8.6% weight-loss finding came from a small sixteen-week cohort. Its comparator, analysis and exposure explain how to interpret it.
Read article181–192 of 323 articles